PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.05
D/E ratio at 50-90% of Drug Manufacturers - Specialty & Generic median of 0.07. Peter Lynch would verify if this conservative capital structure supports growth opportunities.
90.49
Dangerously high net debt exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.73. Michael Burry would check for debt covenant compliance and refinancing risks.
-11.40
Negative coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
20.80
Current ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.82. Joel Greenblatt would verify if this conservative approach provides competitive advantages.
1.60%
Intangibles less than half the Drug Manufacturers - Specialty & Generic median of 5.03%. Warren Buffett would verify if this conservative approach misses valuable brand-building opportunities.